RNV

RENERVE FPO [RNV]
ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers Empliq Dermal, an acellular dermal matrix (ADM) sourced from donated human skin and designed to replace lost or damaged dermal tissue; bionic nerve, a novel combination polymer technology; and Nerve Guide Matrix for treating more severe nerve injuries but eliminating the need for patients to undergo additional sural nerve harvesting under the NervAlign brand. The company was incorporated in 2016 and is headquartered in Northcote, Australia.
Healthcare · ASX Small Cap
$0.0740 +0.0%

Updated 9 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-03-03
Get alerts when RNV triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track RNV — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is losing steam
  • Drifting lower — down 3.9% over the last 5 days
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Critical cash runway (1.0 quarters)
  • Strong revenue growth (+104%)
  • Near 52-week low (4% of range)
  • Micro-cap ($5-20M) - high risk
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 54% over the past year
  • Revenue growing at +104% — the top line is moving in the right direction
  • Beneish M-Score 4.88 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Not enough chatter to gauge sentiment — defaulting to neutral

Expected next for RNV

30 Oct 2026Quarterly Cash Flow Report (4C)Estimated from past filings
Window: 23 Oct to 6 Nov
The last 5 moved RNV -0.8% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →

Recent Catalysts

NONE ReNerve and RMIT awarded $499k grant
NONE Notice of Annual General Meeting/Proxy Form
NONE ReNerve - Corporate Governance Statement

Recent ASX Announcements

2026-09-06 ReNerve and RMIT awarded $499k grant PRICE SENSITIVE
2026-09-02 Notice of Annual General Meeting/Proxy Form
2026-08-27 ReNerve - Corporate Governance Statement
2026-08-27 ReNerve - Appendix 4G
2026-08-27 ReNerve - Full Year Results

Key Metrics

$12.8M
Market Cap
48K
Avg Volume
1.7x
Vol Ratio
$0.07 — $0.22
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-133.1%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 54%
LLeader vs LaggardlaggardRS: -8
IInstitutional SponsorshipweakInst: 1%
MMarket DirectionneutralNeutral

Sector: Healthcare

110 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
NUZ +37.1%IPD +20.0%HIQ +16.7%AVE +15.0%CVB +11.1%
Compare:RNV vs NUZRNV vs IPDRNV vs HIQ
Share this analysis

Track RNV and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required